Redox Proteomics and Metabolic Proteins in Brain of Subjects with Alzheimer's Disease, Mild Cognitive Impairment, and Models Thereof

Neural Degeneration and Repair: Gene Expression Profiling, Proteomics and Systems Biology

Volumn , Issue , 2008, Pages 181-207

  Sultana, Rukhsana ^a   Reed, Tanea ^a   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's Disease; Energy related proteins; Metabolic proteins; Mild cognitive impairment; Models thereof; Neural degeneration; Neural repair; Oxidative stress; Redox proteomics

Indexed keywords

EID: 84891008660     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527622467.ch9     Document Type: Chapter

References (192)

1. Stadtman, E.R. and Levine, R.L. (2003) Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids, 25 (3-4), 207-218.
2. Mikkelsen, R.B. and Wardman, P. (2003) Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene, 22 (37), 5734-5754.
3. Thannickal, V.J., Day, R.M., Klinz, S.G., Bastien, M.C., Larios, J.M. and Fanburg, B.L. (2000) Ras-dependent and-independent regulation of reactive oxygen species by mitogenic growth factors and TGF-betal. FASEB Journal, 14 (12), 1741-1748.
4. Sies, H. and Cadenas, E. (1985) Oxidative stress: damage to intact cells and organs. Philosophical Transactions of the Royal Society of London. Series B Biological Sciences, 311 (1152), 617-631.
5. Aksenov, M.Y., Aksenova, M.V., Butterfield, D.A., Geddes, J.W. and Markesbery, W.R. (2001) Protein oxidation in the brain in Alzheimers disease. Neuroscience, 103 (2), 373-383.
6. Baynes, J.W. and Thorpe, S.R. (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radical Biology and Medicine, 28 (12), 1708-1716.
7. Boyd-Kimball, D., Castegna, A., Sultana, R., Poon, H.F., Petroze, R., Lynn, B.C., Klein, J.B. and Butterfield, D.A. (2005) Proteomic identification of proteins oxidized by Abeta(1-42) in synapto-somes: implications for Alzheimer's disease. Brain Research, 1044 (2), 206-215.
8. Butterfield, D.A. (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radical Research, 36 (12), 1307-1313.
9. Butterfield, D.A., Perluigi, M. and Sultana, R. (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. European Journal of Pharmacology, 545 (1), 39-50.
10. Nakamura, K., Hori, T., Sato, N., Sugie, K., Kawakami, T. and Yodoi, J. (1993) Redox regulation of a src family protein tyrosine kinase p56lck in T cells. Oncogene, 8 (11), 3133-3139.
11. Smith, M.A. and Perry, G. (1996) Alzheimer disease: protein-protein interaction and oxidative stress. Boletin de Estudios Medicos Y Biologicos, 44 (1-4), 5-10.
12. Staal, F.J., Anderson, M.T., Staal, G.E., Herzenberg, L.A. and Gitler, C. (1994) Redox regulation of signal transduction: tyrosine phosphorylation and calcium influx. Proceedings of the National Academy of Sciences of the United States of America, 91 (9), 3619-3622.
13. Shen, J., Yang, X., Dong, A., Petters, R.M., Peng, Y.W., Wong, F. and Campochiaro, P.A. (2005) Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. Journal of Cellular Physiology, 203 (3), 457-464.
14. Butterfield, D.A. and Stadtman, E.R. (1997) Protein oxidation processes in aging brain. Advances in Cell Aging and Gerontology, 2, 161-191.
15. Davies, K.J. (2001) Degradationof oxidized proteins by the 20S proteasome. Biochimie, 83 (3-4), 301-310.
16. Shacter, E. (2000) Quantification and significance of protein oxidation in biological samples. Drug Metabolism Reviews, 32 (3-4), 307-326.
17. Lafon-Cazal, M., Culcasi, M., Gaven, F., Pietri, S. and Bockaert, J. (1993) Nitric oxide superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar granule cells. Neuropharmacology, 32 (11), 1259-1266.
18. Calabrese, V., Scapagnini, G., Colombrita, C., Ravagna, A., Pennisi, G., Giuffrida Stella, A.M., Galli, F. and Butterfield, D.A. (2003) Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids, 25 (3-4), 437-444.
19. Calabrese, V., Scapagnini, G., Ravagna, A., Bella, R., Butterfield, D.A., Calvani, M., Pennisi, G. and Giuffrida Stella, A.M. (2003) Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochemical Research, 28 (9), 1321-1328.
20. Poon, H.F., Calabrese, V., Scapagnini, G. and Butterfield, D.A. (2004) Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. Journals of Gerontology. Series A Biological Sciences and Medical Sciences, 59 (5), 478-493.
21. Stadtman, E.R. and Berlett, B.S. (1997) Reactive oxygen-mediated protein oxidation in aging and disease. Chemical Research in Toxicology, 10 (5), 485-494.
22. Budanov, A.V., Sablina, A.A., Feinstein, E., Koonin, E.V. and Chumakov, P.M. (2004) Regeneration ofperoxiredoxins by p53-regulated sestrins homologs of bacterial AhpD. Science, 304 (5670), 596-600.
23. Levine, R.L., Wehr, N., Williams, J.A., Stadtman, E.R. and Shacter, E. (2000) Determination of carbonyl groups in oxidized proteins. Methods in Molecular Biology, 99, 15-24.
24. Dalle-Donne, I., Scaloni, A. and Butterfield, D.A. (2006) Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases, John Wiley & Sons, Ltd, Hoboken, NJ.
25. Dalle-Donne, I., Scaloni, A., Giustarini, D., Cavarra, E., Tell, G., Lungarella, G., Colombo, R., Rossi, R. and Milzani, A. (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrometry Reviews, 24 (1), 55-99.
26. Grune, T., Reinheckel, T. and Davies, K.J. (1997) Degradation of oxidized proteins in mammalian cells. FASEB Journal, 11 (7), 526-534.
27. Stadtman, E.R., Oliver, C.N., Levine, R.L., Fucci, L. and Rivett, A.J. (1988) Implication of protein oxidation in protein turnover aging, and oxygen toxicity. Basic Life Science, 49, 331-339.
28. Fucci, L., Oliver, C.N., Coon, M.J. and Stadtman, E.R. (1983) Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing. Proceedings of the National Academy of Sciences of the United States of America, 80 (6), 1521-1525.
29. Shacter, E., Williams, J.A., Lim, M. and Levine, R.L. (1994) Differential susceptibility of plasma proteins to oxidative modification: examination by Western blot immunoassay. Free Radical Biology and Medicine, 17 (5), 429-437.
30. Keller, J.N., Hanni, K.B. and Markesbery, W.R. (2000) Impaired proteasome function in Alzheimer's disease. Journal of Neurochemistry, 75 (1), 436-439.
31. Petropoulos, I., Conconi, M., Wang, X., Hoenel, B., Bregegere, F., Milner, Y. and Friguet, B. (2000) Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. Journals of Gerontology. Series A Biological Sciences and Medical Sciences, 55 (5), B220-B227.
32. Starke-Reed, P.E. and Oliver, C.N. (1989) Protein oxidation and proteolysis during aging and oxidative stress. Archives of Biochemistry and Biophysics, 275 (2), 559-567.
33. Szweda, P.A., Friguet, B. and Szweda, L.I. (2002) Proteolysis free radicals, and aging. Free Radical Biology and Medicine, 33 (1), 29-36.
34. Rivett, A.J. (1986) Regulation of intracellular protein turnover: covalent modification as a mechanism ofmarking proteins for degradation. Current Topics in Cellular Regulation, 28, 291-337.
35. Sitte, N., Huber, M., Grune, T., Ladhoff, A., Doecke, W.D., Von Zglinicki, T. and Davies, K.J. (2000) Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. FASEB Journal, 14 (11), 1490-1498.
36. Stadtman, E.R. and Levine, R.L. (2000) Protein oxidation. Annals of the New York Academy of Sciences, 899, 191-208.
37. Lauderback, C.M., Hackett, J.M., Huang, F.F., Keller, J.N., Szweda, L.I., Markesbery, W.R. and Butterfield, D.A. (2001) The glial glutamate transporter GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta 1-42. Journal of Neurochemistry, 78 (2), 413-416.
38. Sultana, R. and Butterfield, D.A. (2004) Oxidatively modified GSTand MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochemical Research, 29, 2215-2220.
39. Aksenova, M., Butterfield, D.A., Zhang, S.X., Underwood, M. and Geddes, J.W. (2002) Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. Journal of Neurotrauma, 19 (4), 491-502.
40. Roix, J. and Misteli, T. (2002) Genomes proteomes, and dynamic networks in the cell nucleus. Histochemistry and Cell Biology, 118 (2), 105-116.
41. Rabilloud, T. (2002) Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics, 2, 3-10.
42. Stevens, S.M., Jr, Kem, W.R. and Prokai, L. (2002) Investigation of cytolysin variants by peptide mapping: enhanced protein characterization using complementary ionization and mass spectrometric techniques. Rapid Communications in Mass Spectrometry, 16 (22), 2094-2101.
43. Wagner, Y., Sickmann, A., Meyer, H.E. and Daum, G. (2003) Multidimensional nano-HPLC for analysis of protein complexes. Journal of the American Societyfor Mass Spectrometry, 14 (9), 1003-1011.
44. Smolka, M.B., Zhou, H., Purkayastha, S. and Aebersold, R. (2001) Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Analytical Biochemistry, 297 (1), 25-31.
45. Anderson, N.L., Matheson, A.D. and Steiner, S. (2000) Proteomics: applications in basic and applied biology. Current Opinion in Biotechnology, 11 (4), 408-412.
46. O'Farrell, P.H. (1975) High resolution two-dimensional electrophoresis of proteins. The Journal of Biological Chemistry, 250 (10), 4007-4021.
47. Tilleman, K., Stevens, I., Spittaels, K., Haute, C.V., Clerens, S., Van Den Bergh, G., Geerts, H., Van Leuven, F., Vandesande, F. and Moens, L. (2002) Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: a proteomics point of view. Proteomics, 2 (1), 94-104.
48. Santoni, V., Molloy, M. and Rabilloud, T. (2000) Membrane proteins and proteomics: un amour impossible? Electrophoresis, 21 (6), 1054-1070.
49. Boyd-Kimball, D., Poon, H.F., Lynn, B.C., Cai, J., Pierce, W.M., Jr, Klein, J.B., Ferguson, J., Link, C.D. and Butterfield, D.A. (2006) Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease. Neurobiology of Aging, 27 (9), 1239-1249.
50. Hoogland, C., Sanchez, J.C., Tonella, L., Binz, P.A., Bairoch, A., Hochstrasser, D.F. and Appel, R.D. (2000) The 1999 SWISS-2DPAGE database update. Nucleic Acids Research, 28 (1), 286-288.
51. Beal, M.F. (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochimica et Biophysica Acta, 1366 (1-2), 211-223.
52. Mecocci, P., Beal, M.F., Cecchetti, R., Polidori, M.C., Cherubini, A., Chionne, F., Avellini, L., Romano, G. and Senin, U. (1997) Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Molecular and Chemical Neuropathology, 31 (1), 53-64.
53. Sultana, R., Perluigi, M. and Butterfield, D.A. (2006) Redox proteomics identification of oxidatively modified proteins in Alzheimers disease brain and in vivo and in vitro models of AD centered around Abeta (1-42). Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 833 (1), 3-11.
54. Katzman, R. and Saitoh, T. (1991) Advances in Alzheimer's disease. FASEB Journal, 5 (3), 278-286.
55. Cohen, M.L., Golde, T.E., Usiak, M.F., Younkin, L.H. and Younkin, S.G. (1988) in situ hybridization of nucleus basalis neurons shows increased beta-amyloid mRNA in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 85 (4), 1227-1231.
56. Palmert, M.R., Golde, T.E., Cohen, M.L., Kovacs, D.M., Tanzi, R.E., Gusella, J.F., Usiak, M.F., Younkin, L.H. and Younkin, S.G. (1988) Amyloid protein precursor messenger RNAs: differential expression in Alzheimer's disease. Science, 241 (4869), 1080-1084.
57. Trojanowski, J.Q. and Lee, V.M. (2002) The role of tau in Alzheimer's disease. The Medical Clinics of North America, 86 (3), 615-627.
58. Butterfield, D.A., Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends in Molecular Medicine, 7 (12), 548-554.
59. Ho, G.J., Drego, R., Hakimian, E. and Masliah, E. (2005) Mechanisms of cell signaling and inflammation in Alzheimer's disease. Current Drug Targets-Inflammation and Allergy, 4 (2), 247-256.
60. Hynd, M.R., Scott, H.L. and Dodd, P.R. (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochemistry International, 45 (5), 583-595.
61. Markesbery, W.R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biology and Medicine, 23 (1), 134-147.
62. Rego, A.C. and Oliveira, C.R. (2003) Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochemical Research, 28 (10), 1563-1574.
63. Tuppo, E.E. and Arias, H.R. (2005) The role of inflammation in Alzheimer's disease. The International Journal of Biochemistry and Cell Biology, 37 (2), 289-305.
64. Ischiropoulos, H. and Beckman, J.S. (2003) Oxidative stress and nitration in neurodegeneration: cause effect, or association? Journal of Clinical Investigation, 111 (2), 163-169.
65. Butterfield, D.A. and Lauderback, C.M. (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radical Biology and Medicine, 32 (11), 1050-1060.
66. Markesbery, W.R. and Carney, J.M. (1999) Oxidative alterations in Alzheimer's disease. Brain Pathology, 9 (1), 133-146.
67. Smith, M.A., Nunomura, A., Zhu, X., Takeda, A. and Perry, G. (2000) Metabolic metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxidants and Redox Signalling, 2 (3), 413-420.
68. Smith, M.A., Richey Harris, P.L., Sayre, L.M., Beckman, J.S. and Perry, G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. Journal of Neuroscience, 17 (8), 2653-2657.
69. Calabrese, V., Butterfield, D.A. and Stella, A.M. (2003) Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuropro-tection in Alzheimer's disease. Italian Journal of Biochemistry, 52 (4), 177-181.
70. Choi, J., Rees, H.D., Weintraub, S.T., Levey, A.I., Chin, L.S. and Li, L. (2005) Oxidative modifications and aggregation of Cu Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. The Journal of Biological Chemistry, 280 (12), 11648-11655.
71. Dore, S. (2002) Decreased activity of the antioxidant heme oxygenase enzyme: implications in ischemia and in Alzheimer's disease. Free Radical Biology and Medicine, 32 (12), 1276-1282.
72. Lovell, M.A., Ehmann, W.D., Butler, S.M. and Markesbery, W.R. (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology, 45 (8), 1594-1601.
73. Lovell, M.A., Xie, C., Gabbita, S.P. and Markesbery, W.R. (2000) Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain. Free Radical Biology and Medicine, 28 (3), 418-427.
74. Ramassamy, C., Averill, D., Beffert, U., Bastianetto, S., Theroux, L., Lussier-Cacan, S., Cohn, J.S., Christen, Y., Davignon, J., Quirion, R. and Poirier, J. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radical Biology and Medicine, 27 (5-6), 544-553.
75. Good, P.F., Werner, P., Hsu, A., Olanow, C.W. and Perl, D.P. (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. American Journal of Pathology, 149 (1), 21-28.
76. Hensley, K., Hall, N., Subramaniam, R., Cole, P., Harris, M., Aksenov, M., Aksenova, M., Gabbita, S.P., Wu, J.F., Carney, J.M., Lovell, M., Markesbery, W.R. and Butterfield, D.A. (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. Journal of Neurochemistry, 65 (5), 2146-2156.
77. Sayre, L.M., Zelasko, D.A., Harris, P.L., Perry, G., Salomon, R.G. and Smith, M.A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Journal of Neurochemistry, 68 (5), 2092-2097.
78. Rottkamp, C.A., Raina, A.K., Zhu, X., Gaier, E., Bush, A.I., Atwood, C.S., Chevion, M., Perry, G. and Smith, M.A. (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radical Biology and Medicine, 30 (4), 447-450.
79. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q. and Lee, V.M. (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. Journal of Neuroscience, 21 (12), 4183-4187.
80. Yan, S.D., Yan, S.F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M.A., Perry, G., Godman, G.C., Nawroth, P., Zweier, J.L. and Stern, D. (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nature Medicine, 1 (7), 693-699.
81. Drake, J., Link, C.D. and Butterfield, D.A. (2003) Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiology of Aging, 24 (3), 415-420.
82. Curtain, C.C., Ali, F., Volitakis, I., Cherny, R.A., Norton, R.S., Beyreuther, K., Barrow, C.J., Masters, C.L., Bush, A.I. and Barnham, K.J. (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. Journal of Biological Chemistry, 276 (23), 20466-20473.
83. Obrenovich, M.E., Joseph, J.A., Atwood, C.S., Perry, G. and Smith, M.A. (2002) Amyloid-beta: a (life) preserver for the brain. Neurobiology of Aging, 23 (6), 1097-1099.
84. Opazo, C., Huang, X., Cherny, R.A., Moir, R.D., Roher, A.E., White, A.R., Cappai, R., Masters, C.L., Tanzi, R.E., Inestrosa, N.C. and Bush, A.I. (2002) Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine cholesterol, and biological reducing agents to neurotoxic H(2)O(2). The Journal of Biological Chemistry, 277 (43), 40302-40308.
85. Zou, K., Gong, J.S., Yanagisawa, K. and Michikawa, M. (2002) A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. Journal of Neuroscience, 22 (12), 4833-4841.
86. Casserly, I. and Topol, E. (2004) Convergence of atherosclerosis and Alzheimer's disease: inflammation cholesterol, and misfolded proteins. Lancet, 363 (9415), 1139-1146.
87. Colton, C.A. (1994) Microglial oxyradical production: causes and consequences. Neuropathology and Applied Neurobiology, 20 (2), 208-209.
88. Mohmmad Abdul, H., Sultana, R., Keller, J.N., St Clair, D.K., Markesbery, W.R. and Butterfield, D.A. (2006) Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42) HO and kainic acid: implications for Alzheimer's disease. Journal of Neurochemistry, 96 (5), 1322-1335.
89. Summers, W.K. (2004) Alzheimer's disease, oxidative injury, and cytokines. Journal of Alzheimer's Disease, 6 (6), 651-657, discussion 673-681.
90. Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J.B., Pierce, W.M., Booze, R., Markesbery, W.R. and Butterfield, D.A. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology and Medicine, 33 (4), 562-571.
91. Castegna, A., Aksenov, M., Thongboonkerd, V., Klein, J.B., Pierce, W.M., Booze, R., Markesbery, W.R. and Butterfield, D.A. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2 alpha-enolase and heat shock cognate 71. Journal of Neurochemistry, 82 (6), 1524-1532.
92. Castegna, A., Thongboonkerd, V., Klein, J.B., Lynn, B., Markesbery, W.R. and Butterfield, D.A. (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. Journal of Neurochemistry, 85 (6), 1394-1401.
93. Sultana, R., Boyd-Kimball, D., Poon, H.F., Cai, J., Pierce, W.M., Klein, J.B., Merchant, M., Markesbery, W.R. and Butterfield, D.A. (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neuro-biology of Aging, 27 (11), 1564-1576.
94. Sultana, R., Poon, H.F., Cai, J., Pierce, W.M., Merchant, M., Klein, J.B., Markesbery, W.R. and Butterfield, D.A. (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiology of Disease, 22 (1), 76-87.
95. Yu, H.L., Chertkow, H.M., Bergman, H. and Schipper, H.M. (2003) Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics, 3 (11), 2240-2248.
96. Choi, J., Malakowsky, C.A., Talent, J.M., Conrad, C.C. and Gracy, R.W. (2002) Identification of oxidized plasma proteins in Alzheimer's disease. Biochemical and Biophysical Research Communications, 293 (5), 1566-1570.
97. Hensley, K., Maidt, M.L., Yu, Z., Sang, H., Markesbery, W.R. and Floyd, R.A. (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. Journal of Neuroscience, 18 (20), 8126-8132.
98. Butterfield, D.A., Poon, H.F., St Clair, D., Keller, J.N., Pierce, W.M., Klein, J.B. and " Markesbery, W.R. (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiology of Disease, 22 (2), 223-232.
99. Choi, J., Levey, A.I., Weintraub, S.T., Rees, H.D., Gearing, M., Chin, L.S. and Li, L. (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. Journal of Biological Chemistry, 279 (13), 13256-13264.
100. Gong, B., Cao, Z., Zheng, P., Vitolo, O.V., Liu, S., Staniszewski, A., Moolman, D., Zhang, H., Shelanski, M. and Arancio, O. (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell, 126 (4), 775-788.
101. Blass, J.P., Sheu, R.K. and Cedarbaum, J.M. (1988) Energy metabolism in disorders of the nervous system. Revue Neurologique (Paris), 144 (10), 543-563.
102. Blass, J.P., Sheu, R.K. and Gibson, G.E. (2000) Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Annals of the New York Academy of Sciences, 903, 204-221.
103. Vannucci, R.C. and Vannucci, S.J. (2000) Glucose metabolism in the developing brain. Seminars in Perinatology, 24 (2), 107-115.
104. Harr, S.D., Simonian, N.A. and Hyman, B.T. (1995) Functional alterations in Alzheimer's disease: decreased glucose transporter 3 immunoreactivity in the perforant pathway terminal zone. Journal of Neuropathology and Experimental Neurology, 54 (1), 38-41.
105. Messier, C. and Gagnon, M. (1996) Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behavioural Brain Research, 75 (1-2), 1-11.
106. Rapoport, S.I. (1999) in vivo PETimaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 249 (Suppl. 3), 46-55.
107. Vanhanen, M. and Soininen, H. (1998) Glucose intolerance cognitive impairment and Alzheimer's disease. Current Opinion in Neurology, 11 (6), 673-677.
108. Geddes, J.W., Pang, Z. and Wiley, D.H. (1996) Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease. Molecular and Chemical Neuropathology, 28 (1-3), 65-74.
109. Ibanez, V., Pietrini, P., Alexander, G.E., Furey, M.L., Teichberg, D., Rajapakse, J.C., Rapoport, S.I., Schapiro, M.B. and Horwitz, B. (1998) Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology, 50 (6), 1585-1593.
110. Reiman, E.M., Caselli, R.J., Yun, L.S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S.N. and Osborne, D. (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. New England Journal of Medicine, 334 (12), 752-758.
111. Cheng, B. and Mattson, M.P. (1992) Glucose deprivation elicits neuro-fibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Experimental Neurology, 117 (2), 114-123.
112. Castegna, A., Lauderback, C.M., Mohmmad-Abdul, H. and Butterfield, D.A. (2004) Modulation of phospho-lipid asymmetry in synaptosomal membranes by the lipid peroxidation products 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Research, 1004 (1-2), 193-197.
113. Mohmmad Abdul, H. and Butterfield, D.A. (2005) Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synapto-somal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. Biochimica et Biophysica Acta, 1741 (1-2), 140-148.
114. Planel, E., Miyasaka, T., Launey, T., Chui, D.H., Tanemura, K., Sato, S., Murayama, O., Ishiguro, K., Tatebayashi, Y. and Takashima, A. (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. Journal of Neuroscience, 24 (10), 2401-2411.
115. Iwangoff, P., Armbruster, R., Enz, A. and Meier-Ruge, W. (1980) Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mechanisms of Ageingand Development, 14 (1-2), 203-209.
116. Meier-Ruge, W., Iwangoff, P. and Reichlmeier, K. (1984) Neurochemical enzyme changes in Alzheimer's and Pick's disease. Archives of Gerontology and Geriatrics, 3 (2), 161-165.
117. Junge, W., Lill, H. and Engelbrecht, S. (1997) ATP synthase: an electrochemical transducer with rotatory mechanics. Trends in Biochemical Sciences, 22 (11), 420-423.
118. Sergeant, N., Wattez, A., Galvan-valencia, M., Ghestem, A., David, J.P., Lemoine, J., Sautiere, P.E., Dachary, J., Mazat, J.P., Michalski, J.C., Velours, J., Mena-Lopez, R. and Delacourte, A. (2003) Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience, 117 (2), 293-303.
119. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. and Yankner, B.A. (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron, 33 (5), 677-688.
120. Petersen, R.C. (2004) Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256 (3), 183-194.
121. Visser, P.J., Verhey, F.R., Ponds, R.W. and Jolles, J. (2001) Diagnosis of preclinical Alzheimer's disease in a clinical setting. International Psycho-geriatrics, 13 (4), 411-423.
122. Almkvist, O., Axelman, K., Basun, H., Jensen, M., Viitanen, M., Wahlund, L.O. and Lannfelt, L. (2003) Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment. Acta Neurologica Scandinavica Supplementum, 179, 77-82.
123. Nacmias, B., Piccini, C., Bagnoli, S., Tedde, A., Cellini, E., Bracco, L. and Sorbi, S. (2004) Brain-derived neurotrophic factor apolipoprotein E genetic variants and cognitive performance in Alzheimer's disease. Neuroscience Letters, 367 (3), 379-383.
124. Traykov, L., Rigaud, A.S., Baudic, S., Smagghe, A., Boller, F. and Forette, F. (2002) Apolipoprotein E epsilon 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease. Journal of the Neurological Sciences, 203-204, 177-181.
125. Barnes, D.E. and Yaffe, K. (2005) Vitamin E and donepezil for the treatment ofmild cognitive impairment. New England Journal of Medicine, 353 (9), 951-952, author reply 951-952.
126. Guidi, I., Galimberti, D., Lonati, S., Novembrino, C., Bamonti, F., Tiriticco, M., Fenoglio, C., Venturelli, E., Baron, P., Bresolin, N. and Scarpini, E. (2006) Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 27 (2), 262-269.
127. Mecocci, P., Mariani, E., Cornacchiola, V. and Polidori, M.C. (2004) Antioxidants for the treatment of mild cognitive impairment. Neurological Research, 26 (5), 598-602.
128. Rinaldi, P., Polidori, M.C., Metastasio, A., Mariani, E., Mattioli, P., Cherubini, A., Catani, M., Cecchetti, R., Senin, U. and Mecocci, P. (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimers disease. Neurobiology of Aging, 24 (7), 915-919.
129. Butterfield, D.A., Reed, T., Perluigi, M., De Marco, C., Coccia, R., Cini, C. and Sultana, R. (2006) Elevated protein-bound levels of the lipid peroxidation product 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neuroscience Letters, 397 (3), 170-173.
130. Keller, J.N., Schmitt, F.A., Scheff, S.W., Ding, Q., Chen, Q., Butterfield, D.A. and Markesbery, W.R. (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology, 64 (7), 1152-1156.
131. Ding, Q., Markesbery, W.R., Cecarini, V. and Keller, J.N. (2006) Decreased RNA and increased RNA oxidation, in Ribosomes from early Alzheimer's disease. Neurochemical Research. 31 (5), 705-710.
132. Wang, J., Markesbery, W.R. and Lovell, M.A. (2006) Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. Journal of Neurochemistry, 96 (3), 825-832.
133. Markesbery, W.R., Kryscio, R.J., Lovell, M.A. and Morrow, J.D. (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of Neurology, 58 (5), 730-735.
134. German, D.C. and Eisch, A.J. (2004) Mouse models of Alzheimer's disease: insight into treatment. Reviews in the Neurosciences, 15 (5), 353-369.
135. Siman, R., Reaume, A.G., Savage, M.J., Trusko, S., Lin, Y.G., Scott, R.W. and Flood, D.G. (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production amyloid deposition, and neuronal vulnerability. Journal of Neuroscience, 20 (23), 8717-8726.
136. Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., Borghgraef, P. and Van Leuven, F. (2005) Changed conformation of mutant Tau-P301L underlies the moribund tauopathy absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. The Journal of Biological Chemistry, 280 (5), 3963-3973.
137. Castegna, A., Thongboonkerd, V., Klein, J., Lynn, B.C., Wang, Y.L., Osaka, H., Wada, K. and Butterfield, D.A. (2004) Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. Journal of Neurochemistry, 88 (6), 1540-1546.
138. Boyd-Kimball, D., Sultana, R., Poon, H.F., Mohmmad-Abdul, H., Lynn, B.C., Klein, J.B. and Butterfield, D.A. (2005) Gamma-glutamylcysteine ethyl ester protection of proteins from Abeta(1-42)-mediated oxidative stress in neuronal cell culture: a proteomics approach. Journal of Neuroscience Research, 79 (5), 707-713.
139. Sultana, R., Newman, S.F., Abdul, H.M., Cai, J., Pierce, W.M., Klein, J.B., Merchant, M. and Butterfield, D.A. (2006) Protective effect of D609 against amyloid-beta1-42-induced oxidative modification of neuronal proteins: redox proteomics study. Journal of Neuroscience Research, 84 (2), 409-417.
140. Dhar-Chowdhury, P., Harrell, M.D., Han, S.Y., Jankowska, D., Parachuru, L., Morrissey, A., Srivastava, S., Liu, W., Malester, B., Yoshida, H. and Coetzee, W.A. (2005) The glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase, triose-phosphate isomerase, and pyruvate kinase are components of the K(ATP) channel macromolecular complex and regulate its function. Journal of Biological Chemistry, 280 (46), 38464-38470.
141. Sirover, M.A. (1997) Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. Journal of Cellular Biochemistry, 66 (2), 133-140.
142. Tatton, W.G., Chalmers-Redman, R.M., Elstner, M., Leesch, W., Jagodzinski, F.B., Stupak, D.P., Sugrue, M.M. and Tatton, N.A. (2000) Glyceraldehyde-3-phosphate dehydrogenase in neuro-degeneration and apoptosis signaling. Journal of Neural Transmission, (Suppl. 60), 77-100.
143. Chuang, D.M., Hough, C. and Senatorov, V.V. (2005) Glyceraldehyde-3-phosphate dehydrogenase apoptosis, and neurodegenerative diseases. Annual Review of Pharmacology and Toxicology, 45, 269-290.
144. Hara, M.R., Cascio, M.B. and Sawa, A. (2006) GAPDH as a sensor of NO stress. Biochimica et Biophysica Acta, 1762 (5), 502-509.
145. Miyamoto, M. (1997) Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Experimental Gerontology, 32 (1-2), 139-148.
146. Takeda, T., Hosokawa, M. and Higuchi, K. (1997) Senescence-accelerated mouse (SAM): a novel murine model of senescence. Experimental Gerontology, 32 (1-2), 105-109.
147. Flood, J.F. and Morley, J.E. (1998) Learning and memory in the SAMP8 mouse. Neuroscience and Biobehavioral Reviews, 22 (1), 1-20.
148. Kumar, V.B., Farr, S.A., Flood, J.F., Kamlesh, V., Franko, M., Banks, W.A. and Morley, J.E. (2000) Site-directed antisense oligonucleotide decreases the expression ofamyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides, 21 (12), 1769-1775.
149. Morley, J.E., Kumar, V.B., Bernardo, A.E., Farr, S.A., Uezu, K., Tumosa, N. and Flood, J.F. (2000) Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides, 21 (12), 1761-1767.
150. Butterfield, D.A., Howard, B.J., Yatin, S., Allen, K.L. and Carney, J.M. (1997) Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proceedings of the National Academy of Sciences of the United States of America, 94 (2), 674-678.
151. Fujibayashi, Y., Yamamoto, S., Waki, A., Konishi, J. and Yonekura, Y. (1998) Increased mitochondrial DNA deletion in the brain of SAMP8 a mouse model for spontaneous oxidative stress brain. Neuroscience Letters, 254 (2), 109-112.
152. Nishikawa, T., Takahashi, J.A., Fujibayashi, Y., Fujisawa, H., Zhu, B., Nishimura, Y., Ohnishi, K., Higuchi, K., Hashimoto, N. and Hosokawa, M. (1998) An early stage mechanism of the age-associated mitochondrial dysfunction in the brain of SAMP8 mice: an age-associated neurodegeneration animal model. Neuroscience Letters, 254 (2), 69-72.
153. Banks, W.A., Farr, S.A., Butt, W., Kumar, V.B., Franko, M.W. and Morley, J.E. (2001) Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. Journal of Pharmacology and Experimental Therapeutics, 297 (3), 1113-1121.
154. Banks, W.A., Robinson, S.M., Verma, S. and Morley, J.E. (2003) Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: impairment in a mouse model of Alzheimers disease. Neuroscience, 121 (2), 487-492.
155. Poon, H.F., Joshi, G., Sultana, R., Farr, S.A., Banks, W.A., Morley, J.E., Calabrese, V. and Butterfield, D.A. (2004) Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Research, 1018 (1), 86-96.
156. Kumar, V.B., Franko, M.W., Farr, S.A., Armbrecht, H.J. and Morley, J.E. (2000) Identification of age-dependent changes in expression of senescence-accelerated mouse (SAMP8) hippocampal proteins by expression array analysis. Biochemical and Biophysical Research Communications, 272 (3), 657-661.
157. Poon, H.F., Castegna, A., Farr, S.A., Thongboonkerd, V., Lynn, B.C., Banks, W.A., Morley, J.E., Klein, J.B. and Butterfield, D.A. (2004) Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience, 126 (4), 915-926.
158. Wei, X., Zhang, Y. and Zhou, J. (1999) Alzheimer's disease-related gene expression in the brain of senescence accelerated mouse. Neuroscience Letters, 268 (3), 139-142.
159. Wei, X., Zhang, Y. and Zhou, J. (1999) Differential display and cloning of the hippocampal gene mRNas in senescence accelerated mouse. Neuroscience Letters, 275 (1), 17-20.
160. Kumar, V.B., Vyas, K., Buddhiraju, M., Alshaher, M., Flood, J.F. and Morley, J.E. (1999) Changes in membrane fatty acids and delta-9 desaturase in senescence accelerated (SAMP8) mouse hippocampus with aging. Life Sciences, 65 (16), 1657-1662.
161. Okatani, Y., Wakatsuki, A., Reiter, R.J. and Miyahara, Y. (2002) Melatonin reduces oxidative damage ofneural lipids and proteins in senescence-accelerated mouse. Neurobiology of Aging, 23 (4), 639-644.
162. Sato, E., Oda, N., Ozaki, N., Hashimoto, S., Kurokawa, T. and Ishibashi, S. (1996) Early and transient increase in oxidative stress in the cerebral cortex of senescence-accelerated mouse. Mechanisms of Ageing and Development, 86 (2), 105-114.
163. Kurokawa, T., Sato, E., Inoue, A. and Ishibashi, S. (1996) Evidence that glucose metabolism is decreased in the cerebrum of aged female senescence-accelerated mouse: possible involvement of a low hexokinase activity. Neuroscience Letters, 214 (1), 45-48.
164. Shimano, Y. (1998) Studies on aging through analysis of the glucose metabolism related to the ATP-production of the senescence accelerated mouse (SAM). Hokkaido Igaku Zasshi, 73 (6), 557-569.
165. Bendiske, J., Caba, E., Brown, Q.B. and Bahr, B.A. (2002) Intracellular deposition microtubule destabilization, and transport failure: an "early" pathogenic cascade leading to synaptic decline. Journal of Neuropathology and Experimental Neurology, 61 (7), 640-650.
166. Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W., Jr and Morris, J.C. (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 56 (1), 127-129.
167. Scheff, S.W., Price, D.A., Schmitt, F.A. and Mufson, E.J. (2005) Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging. 27 (10), 1372-1384.
168. Lassmann, H. (1996) Patterns of synaptic and nerve cell pathology in Alzheimer's disease. Behavioural Brain Research, 78 (1), 9-14.
169. Reddy, P.H., Mani, G., Park, B.S., Jacques, J., Murdoch, G., Whetsell, W., Jr, Kaye, J. and Manczak, M. (2005) Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. Journal of Alzheimer's Disease, 7 (2), 103-117, discussion 173-180.
170. Eckert, G.P., Wood, W.G. and Muller, W.E. (2005) Membrane disordering effects of beta-amyloid peptides. Subcellular Biochemistry, 38, 319-337.
171. Gylys, K.H., Fein, J.A., Yang, F., Wiley, D.J., Miller, C.A. and Cole, G.M. (2004) Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. American Journal of Pathology, 165 (5), 1809-1817.
172. Weber, J. and Senior, A.E. (2003) ATP synthesis driven by proton transport in F1F0-ATP synthase. FEBS Letters, 545 (1), 61-70.
173. Cross, R.L. (2000) The rotary binding change mechanism of ATP synthases. Biochimica et Biophysica Acta, 1458 (2-3), 270-275.
174. Fillingame, R.H. (1992) H+ transport and coupling by the F0 sector of the ATP synthase: insights into the molecular mechanism of function. Journal of Bioenergetics and Biomembranes, 24 (5), 485-491.
175. McCabe, M.G., Bourgain, R. and Maguire, D.J. (2003) How proton translocation across mitochondrial inner membranes drives the Fo rotor of ATP synthase. Advances in Experimental Medicine and Biology, 540, 133-138.
176. Nath, S. (2003) Molecular mechanisms of energy transduction in cells: engineering applications and biological implications. Advances in Biochemical Engineering/Biotechnology, 85, 125-180.
177. Strajbl, M., Shurki, A. and Warshel, A. (2003) Converting conformational changes to electrostatic energy in molecular motors: the energetics of ATP synthase. Proceedings of the National Academy of Sciences of the United States of America, 100 (25), 14834-14839.
178. Opie, L.H. and Owen, P. (1975) Effects of increased mechanical work by isolated perfused rat heart during production or uptake of ketone bodies. Assessment of mitochondrial oxidized to reduced free nicotinamide-adenine dinucleotide ratios and oxaloacetate concentrations. The Biochemical Journal, 148 (3), 403-415.
179. Casamenti, F., Prosperi, C., Scali, C., Giovannelli, L. and Pepeu, G. (1998) Morphological biochemical and behavioural changes induced by neuro-toxic and inflammatory insults to the nucleus basalis. International Journal of Developmental Neuroscience, 16 (7-8), 705-714.
180. Bales, K.R., Tzavara, E.T., Wu, S., Wade, M.R., Bymaster, F.P., Paul, S.M. and Nomikos, G.G. (2006) Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. Journal of Clinical Investigation, 116 (3), 825-832.
181. Goekoop, R., Scheltens, P., Barkhof, F. and Rombouts, S.A. (2006) Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-a pharmacological fMRI study. Brain, 129 (Pt 1), 141-157.
182. Muir, J.L., Page, K.J., Sirinathsinghji, D.J., Robbins, T.W. and Everitt, B.J. (1993) Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning memory and attention. Behavioural Brain Research, 57 (2), 123-131.
183. Schliebs, R. (2005) Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neuro-trophin signaling. Neurochemical Research, 30 (6-7), 895-908.
184. Boyd-Kimball, D., Sultana, R., Poon, H.F., Lynn, B.C., Casamenti, F., Pepeu, G., Klein, J.B. and Butterfield, D.A. (2005) ' Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience, 132 (2), 313-324.
185. Giovannini, M.G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M.G., Rosi, S., Pepeu, G. and Casamenti, F. (2002) Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiology of Disease, 11 (2), 257-274.
186. Poon, H.F., Vaishnav, R.A., Getchell, T.V., Getchell, M.L. and Butterfield, D.A. (2006) Quantitative proteomics analysis of differential protein expression and oxidative modification ofspecific proteins in the brains of old mice. Neurobiology of Aging, 27 (7), 1010-1019.
187. Barber, R., McKeith, I.G., Ballard, C., Gholkar, A. and O'Brien, J.T. (2001) A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study. Dementia and Geriatric Cognitive Disorders, 12 (3), 198-205.
188. Convit, A., de Leon, M.J., Golomb, J., George, A.E., Tarshish, C.Y., Bobinski, M., Tsui, W., De Santi, S., Wegiel, J. and Wisniewski, H. (1993) Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. The Psychiatric Quarterly, 64 (4), 371-387.
189. Ishii, K., Sasaki, H., Kono, A.K., Miyamoto, N., Fukuda, T. and Mori, E. (2005) Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies. European Journal of Nuclear Medicine and Molecular Imaging, 32 (8), 959-963.
190. Patel, M.S. and Korotchkina, L.G. (2001) Regulation of mammalian pyruvate dehydrogenase complex by phospho-rylation: complexity of multiple phosphorylation sites and kinases. Experimental and Molecular Medicine, 33 (4), 191-197.
191. Jedrzejas, M.J. (2000) Structure, function, and evolution of phosphoglycerate mutases: comparison with fructose-2, 6-bisphosphatase, acid phosphatase, and alkaline phosphatase. Progress in Biophysics and Molecular Biology, 73 (2-4), 263-287.
192. van der Oost, J., Huynen, M.A. and Verhees, C.H. (2002) Molecular characterization of phosphoglycerate mutase in archaea. FEMS Microbiology Letters, 212 (1), 111-120.